ClinicalTrials.gg
Active, not recruitingNCT07608354ATTRiumphUpdated Jul 14, 2026

A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

A Phase 2 interventional study of Eplontersen and ALXN2220 in Transthyretin Amyloid Cardiomyopathy (ATTR-CM), sponsored by AstraZeneca. Active, not recruiting at 76 sites in 10 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
326
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The purpose of this randomised, double-blind, placebo-controlled, multicenter study is to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

Read the detailed description

This is a Phase IIb, multicenter, double-blind study in 326 participants, who will be randomized to receive either eplontersen and ALXN2220 or eplontersen and placebo once every four weeks. Participants will also receive daily supplemental doses of the recommended daily allowance of vitamin A.

02

Conditions studied

  • Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Keywords

  • Transthyretin amyloid cardiomyopathy
  • ATTR-CM
  • Eplontersen
  • ALXN2220
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Capable of giving .

Inclusion criteria

Inclusion Criteria:

  • Participant must be ≥ 18 years to ≤ 85 years at the time of signing the informed consent.
  • Participants who have a diagnosis of ATTR-CM with either wild-type or variant TTR genotype based on 1 of the following:

    1. Endomyocardial with confirmatory TTR amyloid typing OR
    2. Grade 2 or 3 cardiac uptake on 99mTc scintigraphy in the absence of monoclonal gammopathy OR
    3. Grade 2 or 3 cardiac uptake on 99mTc scintigraphy AND confirmatory TTR amyloid typing in the presence of monoclonal gammopathy.
  • Class I to III at Screening and of ≥ 1 year as per the Investigator's judgement.
  • End-diastolic IVST ≥ 12 mm on echocardiography.
  • NT-proBNP ≥ 600pg/mL for participants without ongoing atrial fibrillation/flutter at Screening or NT-proBNP ≥ 1200pg/mL for participants with ongoing atrial fibrillation/flutter at Screening.
  • Able to complete symptom-limited maximal CPET at Screening based on the following test criteria:

    1. Able to exercise to near exhaustion during CPET as exhibited by RER ≥ 1.0 during symptom-limited CPET conducted during screening.
    2. If participant does not achieve RER ≥1.0, the CPET may be repeated once, at least 48 hours but less than 2 weeks (but before randomization) after the initial test.
  • Treated according to locally recognised guidelines on standard-of-care treatment for patients with HF. Therapy should have been individually optimised and stable for ≥ 4 weeks (except diuretics) and include, unless or not tolerated, treatment of high BP (targeting SBP \< 130 mmHg as suggested in 2022 American College of Cardiology/American Heart Association/Heart Failure Society of America HF guidelines), and ischaemic heart disease.
  • Willingness to adhere to daily self-administered vitamin A supplementation (3000 IU).

Exclusion criteria

Exclusion Criteria:

  • Known amyloidosis.
  • Known light chain (AL) or secondary (amyloid A) amyloidosis, or any other form of systemic amyloidosis.
  • Cardiomyopathy not primarily caused by ATTR-CM, for example, cardiomyopathy primarily due to hypertension, valvular heart disease, or ischaemic heart disease per Investigator's assessment.
  • Acute coronary syndrome, unstable angina, stroke, , coronary revascularisation, cardiac device implantation, cardiac valve repair, or major surgery within 12 weeks of Screening.
  • Uncontrolled hypertension (average resting SBP > 160 mmHg or DBP > 100 mmHg at Screening).
  • Average resting SBP \< 90 mmHg or symptomatic orthostatic hypotension, despite appropriate treatment, at Screening per Investigator's assessment.
  • Uncontrolled ventricular cardiac arrhythmia, per Investigator's assessment.
  • \< 30% on echocardiography measured locally at Screening.
  • Severe pulmonary impairment (SpO₂ \< 92%) defined as resting SpO₂ below 92% on room air, measured by pulse oximetry, indicative of severe lung disease. Participants requiring supplemental oxygen to maintain SpO₂ ≥ 92%.
  • Participants with renal failure requiring dialysis.
  • History of solid organ transplantation or ventricular assist device or listing for heart transplantation at Screening. Note: prior history of planned corneal transplant is not an exclusion criterion.
  • Suspected or known intolerance/allergy to proteins or any components of the study intervention.
  • Any of the following results conducted at screening:

    i) \<8g/dL for women or \<9g/dL for men. ii) count \<125 X10*9/L or other disorder associated with clinically significant thrombocytopenia.

iii) >2.0 X iv) TBL >2.5 X ULN (participants with known Gilbert's syndrome can be included with TBL >2.5 X ULN as long as direct is ≤ 1.5 X ULN) v) Serum retinol level \< LLN vi) By formula, eGFR \<20 mL/min/1.73 m2 measured by the central laboratory at Screening.

  • Current unstable liver or biliary disease per Investigator's assessment.
  • Multiple myeloma, lymphoma, leukemia, or any or clonal stem cell disorder within the past 5 years (except basal cell or squamous epithelial carcinomas of the skin, melanoma in situ or cervical carcinoma in situ that have been curatively resected, Stage I cancer in remission, or adequately treated prostate cancer stage I, IIA, or IIB with Gleason score ≤ 3+4 and prostate-specific antigen \< 20 ng/mL).
  • Any prior treatment with an ATTR amyloid depleter or a TTR gene silencing agent approved or in clinical development.
  • Participated in a structured exercise training programme within the 1 month prior to Screening or planned to start during the trial.
  • Participation in another clinical study or intake of another investigational drug within 30 calendar days or 5 half-lives of the IMP, whichever is longer before signing the ICF.
  • Judgement by the Investigator that the participant should not participate in the study if the participant has a known medical or psychological condition or other risk factor that might interfere with the participant's full participation in the study, pose any additional risk for the participant, or confound the assessment of the participant or outcome of the study.
  • Previous enrolment or randomisation in the present study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
326 participants (estimated)

Study arms

  • Experimental
    Eplontersen and ALXN2220

    Subcutaneous eplontersen and intravenous ALXN2220 every 4 weeks

    Drug: Eplontersen · Biological: ALXN2220

  • Placebo comparator
    Eplontersen and placebo

    Subcutaneous eplontersen and intravenous placebo every 4 weeks

    Drug: Eplontersen · Other: Placebo

Interventions

  • Eplontersen delivered subcutaneously, once every 4 weeks

  • BiologicalALXN2220

    ALXN2220 delivered intravenously, once every 4 weeks

  • OtherPlacebo

    Placebo delivered intravenously, once every 4 weeks

06

What researchers measure

Primary outcomes

  1. Cardiopulmonary exercise test peak VO2

    Change from baseline in Cardiopulmonary exercise test peak VO2 at week 52

    Time frame: 52 week

Secondary outcomes

  1. Extracellular volume

    Change from baseline in Extracellular volume (subgroup) at week 52

    Time frame: 52 week

  2. NT-proBNP

    Change from baseline in NT-proBNP at week 52

    Time frame: 52 week

  3. Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score

    Change from baseline in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score at week 52. The minimum score is 0 and maximum score is 100. Higher scores indicate better health status.

    Time frame: 52 week

07

Study locations

76 sites
  • Research Site
    La Jolla, California 92037, United States
  • Research Site
    San Francisco, California 94115, United States
  • Research Site
    Stanford, California 94305, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Washington D.C., District of Columbia 20010, United States
  • Research Site
    Jacksonville, Florida 32224, United States
  • Research Site
    Miami, Florida 33176, United States
  • Research Site
    Weston, Florida 33331, United States
  • Research Site
    Chicago, Illinois 60637, United States
  • Research Site
    Boston, Massachusetts 02115, United States
  • Research Site
    Kansas City, Missouri 64111, United States
  • Research Site
    St Louis, Missouri 63110, United States
  • Research Site
    New York, New York 10032, United States
  • Research Site
    Chapel Hill, North Carolina 27599, United States
  • Research Site
    Durham, North Carolina 27710, United States
  • Research Site
    Cleveland, Ohio 44195, United States
  • Research Site
    Portland, Oregon 97239, United States
  • Research Site
    Danville, Pennsylvania 17822, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Germantown, Tennessee 38138, United States
  • Research Site
    Dallas, Texas 75390, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Salt Lake City, Utah 84132, United States
  • Research Site
    Falls Church, Virginia 22042, United States
  • Research Site
    Calgary, Alberta T2N 4Z6, Canada
  • Research Site
    Vancouver, British Columbia V6Z 1Y6, Canada
  • Research Site
    Halifax, Nova Scotia B3H 3A7, Canada
  • Research Site
    London, Ontario N6A 5A5, Canada
  • Research Site
    Toronto, Ontario M5G 2C4, Canada
  • Research Site
    Montreal, Quebec H1T 1C8, Canada
  • Research Site
    Beijing, 100034, China
  • Research Site
    Beijing, 100730, China
  • Research Site
    Changsha, 410012, China
  • Research Site
    Chongqing, 400042, China
  • Research Site
    Guangzhou, 510080, China
  • Research Site
    Hangzhou, 310009, China
  • Research Site
    Créteil, 94010, France
  • Research Site
    Marseille, 13005, France
  • Research Site
    Rennes, 35033, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Berlin, 10117, Germany
  • Research Site
    Cologne, 50937, Germany
  • Research Site
    Essen, 45147, Germany
  • Research Site
    Hamburg, 22767, Germany
  • Research Site
    Heidelberg, 69120, Germany
  • Research Site
    Homburg, 66421, Germany
  • Research Site
    München, 81377, Germany
  • Research Site
    Münster, 48149, Germany
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Florence, 50134, Italy
  • Research Site
    Milan, 20138, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Pavia, 27100, Italy
  • Research Site
    Pisa, 56124, Italy
  • Research Site
    Torino, 10154, Italy
  • Research Site
    Torrette - Ancona, 60126, Italy
  • Research Site
    Trieste, IT-34149, Italy
  • Research Site
    Bunkyō City, 113-8431, Japan
  • Research Site
    Kurume-shi, 830-0011, Japan
  • Research Site
    Sapporo, 060-8543, Japan
  • Research Site
    Shinjuku-ku, 160-8582, Japan
  • Research Site
    Suita, 565-8565, Japan
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Jaén, 23007, Spain
  • Research Site
    L'Hospitalet de Llobregat, 08907, Spain
  • Research Site
    Majadahonda, 28222, Spain
  • Research Site
    Málaga, 29010, Spain
  • Research Site
    Pamplona, 31008, Spain
  • Research Site
    Salamanca, 37007, Spain
  • Research Site
    Valencia, 46010, Spain
  • Research Site
    Gothenburg, 413 45, Sweden
  • Research Site
    Lund, 22242, Sweden
  • Research Site
    Stockholm, 171 64, Sweden
  • Research Site
    Uppsala, 751 85, Sweden
  • Research Site
    London, NW10 2PB, United Kingdom
  • Research Site
    London, NW3 2QG, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Feb 2029, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2026
First posted
May 27, 2026
StartActual
Jun 11, 2026
Primary completionEst.
Feb 6, 2029
CompletionEst.
Feb 6, 2029
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07608354
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 27, 2026
Start date
Jun 11, 2026
Primary completion
Feb 6, 2029 (estimated)
Completion
Feb 6, 2029 (estimated)
Last update
Jul 14, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cliramitug

Start the discussion